Navigation Links
BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in China's National Insurance Catalog

PLYMOUTH MEETING, Pa., Dec. 8 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that seventy eight of the Company's drugs have been included in China's National (Medical) Insurance Catalog (the "2009 NIC"), which was released by China's Ministry of Human Resources and Social Security on November 30, 2009 as part of China's health care reform plan. According to the Chinese government, ninety percent of China's citizens will be covered by a universal healthcare system by the end of calendar 2010.

The 2009 NIC is China's health care reform plan's official drug reimbursement list and includes 2,151 drugs in total. Seventy eight of BMP Sunstone's products have been included in the 2009 NIC, twelve of which are new additions from the last published catalog in 2004. These new additions include some of BMP Sunstone's best selling products such as Confort, a women's health treatment for vaginal infections, and Propess, a first line treatment for labor induction in late-stage pregnancy. The Company's Amoxicillin and Amoxicillin & Clavulanate Potassium products, which treat cough and cold symptoms, were also added to the 2009 NIC. In addition, the Company's thalassemia medication, Ferriprox, has been preliminarily added to Guangdong Province's Medical Insurance Catalog.

Mr. David Gao, Chief Executive Officer of BMP Sunstone, commented, "We are delighted to have twelve new drugs and a total of seventy eight of our products included in China's National Insurance Catalog. The NIC is a vital part of the universal healthcare system, and will greatly expand the addressable pharmaceutical market in China. We are especially pleased about the inclusion of two of our best-performing products, Confort and Propess, as well as our cough and cold products, in the NIC and the preliminary inclusion of Ferriprox in Guangdong Province's Medical Insurance Catalog. Guangdong Province has the highest incidence of thalassemia in China and treatment for this disorder can be very expensive. Therefore, we believe that the potential for partial reimbursement in Guangdong Province will boost sales of Ferriprox throughout that province. We believe that the inclusion of our products in the insurance catalogs will strengthen our brand recognition and accelerate our penetration into our key therapeutic areas, including women's and children's health."

About BMP Sunstone Corporation

BMP Sunstone Corporation ("BMP Sunstone" or the "Company") is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone Pharmaceutical Co. Ltd., the Company manufactures leading pediatric and women's health products, including two of China's most recognized brands, "Hao Wawa" and "Confort," sold throughout the country in approximately 120,000 pharmacies. The Company also markets a portfolio of products under exclusive multi-year licenses into China, primarily focused on women's health and pediatrics, as well as provides pharmaceutical distribution services through subsidiaries in Beijing and Shanghai. BMP Sunstone's main office is in Beijing, with a U.S. office in Plymouth Meeting, PA. For more information, please visit .

Safe Harbor Statement

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts, including but not limited to statements about the Company's strategic and market penetration strategies and the potential effects of the listing of the Company's products on China's National (Medical) Insurance Catalog. These statements are subject to uncertainties and risks including, but not limited to, operating performance, general financial, economic, and political conditions affecting the biotechnology and pharmaceutical industries and the Chinese pharmaceutical market, the ability to timely manufacture and distribute the Company's products and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:

    Integrated Corporate Relations, Inc.
    (Investor Relations)

     Ashley M. Ammon
     Tel:   +1-646-277-1227

     Christine Duan
     Tel:   +1-203-682-8200

SOURCE BMP Sunstone Corporation

SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/25/2015)... Developmental, commercial, and regulatory/legal strategies ... of pharmaceutical products, says GBI Research ... strategies all play a key role in boosting the ... . --> Developmental, commercial, ... boosting the profitability of pharmaceutical products, says GBI ...
(Date:11/25/2015)... 2015 ... the  "Global Drug Device Combination Products ... offering.  --> ) ... "Global Drug Device Combination Products Market ... --> Research and Markets ( ...
(Date:11/24/2015)... , Nov. 24, 2015  Natera, ... in non-invasive genetic testing and the analysis ... it will present at the 27 th ... December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., ... financial results, business activities and financial outlook. ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... Tucson, AZ (PRWEB) , ... November 24, 2015 , ... ... iPlus 2.0™ treatments from Dr. Angela Wolfman and Dr. Kedar S. Lele, who are ... used for frenectomies, cavities and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
Breaking Medicine News(10 mins):